Biopharma Development & Production 2018

2018년 5월 15-17일, 중국, 상하이 Hilton Shanghai Hongqiao

Biopharma Development & Production 2018
- 생물의약품 개발 제조 위크 2018 -
일정 : 2018년 5월 15-17일
개최: 중국, 상하이 Hilton Shanghai Hongqiao

 

Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English

Catalog Download
Catalog

개요

중국의 의약품 시장에서 중요한 역할을 담당하고 있는 기업의 임원 등 350여 명이 참가하는 Biopharma Development & Production Week는 제약업계의 연구를 촉진하고 혁신적 기술을 소개하며, 사업면의 네트워킹을 지원하고 있습니다. 컨퍼런스에서는 3개의 컨퍼런스가 동시에 개최되며, 기술 분야와 상업 분야의 토픽에 관한 60여 개의 세션에서 70여 명의 전문가가 강연 등을 진행합니다.

이 이벤트에서는 최신 파괴적 기술의 기반, 신세대 설비, 연속 프로세스 개선 등의 토픽에 관한 고품질의 실용적 정보를 파악할 수 있으며, 세포주, 바이오시밀러, 바이오베터, 항체, 백신, 신규 생물제제의 개발과 제조에 관한 능력을 발전시킬 수 있습니다.



제8회 Biomanufacturing 2018

8:00 am

Registration Opens and Morning Coffee

BIOPHARMA DEVELOPMENT AND PRODUCTION 2018 OPENING PLENARY SESSIONS 2018

9:00 am

Chairperson's Opening Remarks

9:10 am

  • Innovation in biopharma pipelines - what can we expect
  • Recent regulatory developments - obstacle or opportunity?
  • How digitalisation of BioPharma is creating new value propositions
  • Biomanufacturing market snapshot in China
  • Biosimilars market potential - what can we achieve?
  • New trends in cell line development

 

9:50 am

[Industry Address] Understanding the Investment Climate in Biopharma Industry - How is Market Responding to Inflow and Outflow of Investments?

Abrar Mir, Managing Partner, Quadria Capital Investment Management Pte Ltd, Singapore

10:20 am

Transforming BioPharma with Technology and Digitalisation

Wang Honglou, CIO, livzon Pharmaceutical Group, China

10:50 am

Morning Networking and Refreshment Break

END OF OPENING PLENARY AND BIOMANUFACTURING CONFERENCE COMMENCES

11:20 am

Chairperson's Opening Remarks

THE MARKETING AUTHORIZATION HOLDER (MAH) REGIME

11:25 am

  • General requirements for manufacturing of biotech products: current FDA guidances
  • What should be submitted in BLA for US FDA for biotech products including biosimilar products
  • FDA Pre-license inspection coverages: three objectives

11:55 am

  • How CMOs can step up to ensurequality compliance and stable supply chains
  • Opportunities with ‘Infrastructure' improvement
  • Investments needed
  • Ket criteria to make the MAH regime work

More panelists to be confirmed

12:30 pm

Networking Lunch

UTILITY EFFICENCY AND OPTIMIZATION

1:30 pm

  • Biopharmaceuticals booming in marketplace
  • Biomanufacturing facilities sprouting in China
  • Facility design/operation challenging to meet both CFDA and FDA/EMA requirements
  • Examples to illustrate cultural difference as reason

2:00 pm

  • The needs to optimize bioproduction and improve facility utilization
  • Modular continuous processing skids
  • Smart automation enable integrated continuous processing

2:30 pm

Case Study: Building a World-Class Highly Flexible Continuous Manufacturing Facility and Quality System in China

Dr. Frank Ye, SVP of Manufacturing and Quality, Hangzhou Just Biotherapeutics Co., Ltd., China

3:00 pm

Afternoon Teabreak

3:30 pm

Effect of Fully Continuous Process for Mab Manufacturing: Speed to Market and Cost Reduction mAb

Noel Rob, Business Development Manager, Pall Life Sciences, UK

4:00 pm

Innovation in Chromatograpy Platform: Lattice Supported Modular Chromatography using Conventional Resin Enabling Flexible Operations, Linear Scalability & Hyper-Productive Processes

Masayoshi Nagaya, Sr. Global Technology Manager, JSR Life Sciences

4:30 pm

Current Challenges of Biologics Manufacturing in China

Xu Wei, Vice President, Manufacturing, Innovent Biologics, China

5:00 pm

Efficacy of Insulation Systems in Aseptic Areas and Facilities: A Practical Guide to Facility Cost Reduction

David Sadler, President & CEO, Kunshan Zotek Kinglai Co. Ltd. U.K.

5:30 pm

From Process Development to cGMP Manufacturing - Process Control Strategy

Zack Zheng, Ph.D. VP of Process Development (Wuhan), JHL BioTech, China

5:55 pm

Chairperson's Summary and End of Main Conference Day One followed by Networking Cocktail

8:50 am

Chairperson's Opening Remarks

INNOVATIONS IN MANUFACTURING SCIENCE TECHNOLOGY

9:00 am

  • Racing to clinical trials is crucial for startup biotech survival.
  • CMC development is one of the most critical IND enabling deliverables.
  • Leverage phase- and region- appropriate strategies is the key to expedite CMC development and IND filings

9:20 am

Rapid Sterility Testing: A Bioluminescence - Growth Based Approach

John Dubczak, Director of Operations, Charles River Laboratories, U.S.

9:50 am

Perspectives in Process Intensification for mAb Purification mAb

Dr Yvan Ruland, Technology Manager Biopharma, Novasep, China

COLD CHAIN MANAGEMENT

10:20 am

Creating Integrated Visibility, Demand Driven, with Data on Intelligent Cold Chain Solutions

Senior Representative, Envirotainer,

10:40 am

Morning Tea Break

QUALITY COMPLIANCE AND SYSTEMS

11:10 am

Meeting the Quality and Compliance Requirements in Manufacturing Process

Joycelyn Kwek, Former Director, Quality Assurance, Amgen Singapore

11:40 am

Boehringer-Ingelheim, bring your biologics to the clinic and market

Dr. Bin Wang, Head of Business Development, Boehringer Ingelheim Biopharmaceuticals, China

12:10 pm

Networking Lunch

1:10 pm

  • Risk based microbial control strategy
  • Identification and implementation of measures to control the sources of microorganisms and the conditions that promote their survival and persistence
  • Monitoring of the facility, equipment, personnel, process, product and their interactions
  • Intervening or remediating when there is a drift from established controls

1:40 pm

Strategic Practice in Building Quality Management Systems (QMS) in China Facilities

Dr. Dennis Yu Xia, Vice President of Manufacturing and Quality, Akeso Bio, China

FACILITIES AS COMPETITIVE ADVANTAGE

2:10 pm

  • Meeting WHO PQ requirement
  • Streamlining facility concept design to engineering design
  • Building out facility in a quick and efficient way

2:40 pm

Smart Automation: Achieving Increased Productivity through Optimized Asset Utilisation

Dr. Bin Wang, Head of Business Development, Boehringer Ingelheim Biopharmaceuticals, China

3:10 pm

Design, Construction and Commissioning Biomanufacturing Facilities

Yifang Wu, President, Wanbang Biopharmaceuticals Co., Ltd, China

3:40 pm

Afternoon Networking and Refreshment Break

BIOPHARMA DEVELOPMENT & PRODUCTION 2018 CLOSING PLENARY SESSIONS

4:20 pm

  • Enabling drivers of innovation in China
  • Consolidation of local players
  • Shifting investment from manufacturing focus to innovative portfolios
  • Adopting technologies that enable the potential in manufacturing, cell development and similarity
  • Attracting the right talent

5:00 pm

Chairperson's Summary of the Day and End of Conference

9:00 am

Pall has built the capability to offer End 2 End solution for monoclonal antibody manufacturing, both in batch processing and in continuous processing. This workshop will help you to update the newest strategy to build a pilot or commercial facility for Mab manufacturing.

 

4:00 pm

End of workshop

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.



제9회 Biosimilars Asia 2018

8:00 am

Registration Opens and Morning Coffee

BIOPHARMA DEVELOPMENT AND PRODUCTION 2018 OPENING PLENARY SESSIONS

9:00 am

Chairperson's Opening Remarks

9:10 am

  • Innovation in biopharma pipelines - what can we expect
  • Recent regulatory developments - obstacle or opportunity?
  • How digitalisation of BioPharma is creating new value propositions
  • Biomanufacturing market snapshot in China
  • Biosimilars market potential - what can we achieve?
  • New trends in cell line development

9:50 am

[Industry Address] Understanding the Investment Climate in Biopharma Industry - How is Market Responding to Inflow and Outflow of Investments?

Abrar Mir, Managing Partner, Quadria Capital Investment Management Pte Ltd, Singapore

10:20 am

Transforming BioPharma with Technology and Digitalisation

Wang Honglou, CIO, livzon Pharmaceutical Group, China

10:50 am

Morning Networking and Refreshment Break

END OF OPENING PLENARY AND 9TH BIOSIMILARS ASIA CONFERENCE COMMENCES

11:20 am

Changing Landscape of Global Biosimilars Market and What it Means for China?

Dr. Christopher J. Hickey, Senior Director Government Affairs, Market Access & Communications, Pfizer

CHINA'S BIOSIMILARS MARKET

11:40 am

Kerry Inc. Case Study on latest Biosimilars Works

Senior Representative, Kerry Inc., U.S.,

12:30 pm

Networking Lunch

2:00 pm

Managing Costs and Technology Adoption in Biosimilar Development

Manfred Weiler, Senior Vice President, Medical & Scientific Strategy, Syneos Health

3:00 pm

Afternoon Networking & Refreshment Break

3:30 pm

Biosimilars Development in China: Challenges in Bevacizumab Clinical Trial Design

Dr. Jacqueline Ming Liu, Vice President, TOT Biopharma, China

QUALITY AND SIMILARITY ASSESSMENT

4:00 pm

Biosimilar Clinical Materials: Changes and Comparability

Dr Qiwei Wu, Ph.D, Vice President of Process Development and Manufacturing, Livzon Mabpharma

4:35 pm

Fireside Chat: Analytical and Quality Assessment of Biosimilars

Dr Amy Hong Que, Vice President - Quality, Innovent Biologics

5:10 pm

Biological Products Development to Meet International Quality Standards

Dr. Li Shi, Chief Executive Officer, Shanghai Zerun Biotech Co. Ltd

5:45 pm

Chairperson's Summary and End of Main Conference Day One followed by Networking Cocktail

9:00 am

Chairperson's Opening Remarks

GOING GLOBAL AND PARTNERSHIPS

9:10 am

Opening Address: Key Learnings from a Global Perspective How to Unlock the Full Potential of Biosimiliars - Learnings from EU on Access and Procurement

Prof. Dr. Florian Turk, Head Global Payor Marketing, Sales and Relations, Sandoz Biopharmaceuticals Sandoz International GmbH, Germany

9:40 am

Case Study: Global Development Strategy on Biosimilars: How to Win in the International Space

Pearl Fong, Associate Vice President, Division of Project Development, Mycenax Biotech Inc., Taiwan

10:10 am

Biopharma's Case Study: Perspective on Biosimilars Market Development, and China Market Potential and Partnerships

Bryan Kim, Vice President of Business Development, Samsung Bioepis, Korea

10:40 am

Morning Networking & Refreshment Break

SAFETY AND EFFICACY

11:10 am

Clinical Operations and Affairs Study, Safety, Efficacy and Risk

Dr. Xin Zhang, Head of Global Clinical Operations and Affairs, Shanghai Henlius Biotech Co Ltd, China

11:40 am

Pharmacovigilance of Biologics and Biosimilars: Manufacturing, Branding, Post Approval Surveillance for Immunogenicity and Evolving Guidelines

Sunit Maity, Director, Product Development, Zumutor Biologics, India

12:10 pm

Networking Lunch

COMMERCIALISATION OF BIOSIMILARS

1:10 pm

  • Partnership and collaboration models
  • Potential markets for partnerships
  • What are the opportunities for outlicensing

1:50 pm

Establishing Product Development Partnerships

Mitul Agarwal, General Manager - Business Development & Licensing, Intas Pharmaceuticals, India

2:30 pm

Commercialization Practicality: CFDA's Requirement on Biosimilar's Clinical Trial Application

Eric Liu, China Biosimilars Regulation Publishing Manager, Pfizer

3:05 pm

Applying High Throughput Process Development Platform to Develop Downstream Process for Clinical Manufacturing

Jiang Junjun, Assistant Director, WuXi Biologics

3:40 pm

Afternoon Networking and Refreshment Break

BIOPHARMA DEVELOPMENT & PRODUCTION 2018 CLOSING PLENARY SESSIONS

4:20 pm

  • Enabling drivers of innovation in China
  • Consolidation of local players
  • Shifting investment from manufacturing focus to innovative portfolios
  • Adopting technologies that enable the potential in manufacturing, cell development and similarity
  • Attracting the right talent

5:00 pm

Chairperson's Summary of the Day and End of Conference

9:00 am

Pall has built the capability to offer End 2 End solution for monoclonal antibody manufacturing, both in batch processing and in continuous processing. This workshop will help you to update the newest strategy to build a pilot or commercial facility for Mab manufacturing.

 

4:00 pm

End of workshop

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.



제7회 Cell Line Development and Engineering 2018

8:00 am

Registration Opens and Morning Coffee

9:00 am

Chairperson's Opening Remarks

BIOPHARMA DEVELOPMENT AND PRODUCTION 2018 OPENING PLENARY SESSIONS 2018

9:10 am

  • Innovation in biopharma pipelines - what developments can we expect?
  • Recent regulatory developments - obstacle or opportunity?
  • How digitalization of the BioPharma industry is creating new value propositions
  • Biomanufacturing market snapshot in China
  • Biosimilars market potential - what can we achieve?
  • New trends in cell line development

 

 

9:50 am

  • Investment outlook and market drivers for biopharma investments in Asia
  • Taking advantage of a variety of innovative R&D financing and partnership models
  • Assessing current investment climate and its implications on Chinese biotech market

10:20 am

Transforming BioPharma with Technology and Digitalisation

Wang Honglou, CIO, livzon Pharmaceutical Group, China

10:50 am

Morning Networking and Refreshment Break.

END OF OPENING PLENARY AND CELL LINE DEVELOPMENT & ENGINEERING ASIA COMMENCES

11:20 am

Chairperson's Opening Remarks

Sunny Zhou, Professor, Department of Chemistry and Chemical Biology Faculty Fellow, Barnett Institute of Chemical and Biological Analysis Northeastern University, Boston, Massachusetts

CLONE SELECTION STRATEGIES, ESTABLISHING CLONALITY AND STABILITY

11:30 am

  • FDA concerns regarding single cell cloning procedures and assurance of monoclonality
  • Expectations for clonal cell lines
  • Identifying alternative methods and control strategies for establishment of clonality

12:00 pm

 

  • Novel technologies engineered to provide process control while at the same time enabling optimal leverage of the cell factory using ChemStress fingerprinting
  • Utility of CHO cell factories derives from exploitation of their acquired genetic/functional variation, which enable industry to identify cell lineages with desirable manufacturing properties
  • Analyzing cell clone stability profiles using the ChemStress Fingerprint and product-specific algorithms - shortening clone stability assessment timelines and reducing costs

 

12:30 pm

  • Managing cell-line instability and its impact during cell-line development
  • Strategies for faster and more efficient selection of suitable clones
  • Ensuring cell-line stability and clonal heterogeneity

1:00 pm

Networking Lunch and VIP Tables

ADVANCEMENTS IN CELL LINE DEVELOPMENT TECHNIQUES

2:00 pm

  • Overview of the current regulatory position on monoclonality
  • A new, verified, analytical approach to the estimation of the probability of monoclonality that greatly improves the quality of monoclonality reporting in regulatory submissions.
  • Case studies covering the positive impact on workflow and laboratory efficiency
  • Application to CAR-T and targeted gene editing methods such as ZFNs, TALENS and CRISPR/Cas9

2:30 pm

  • Regulatory landscape for cell-line development process
  • Analytical challenges and platforms for characterization of engineered host cell line
  • Determining performance characteristics of engineered cell lines

3:00 pm

Afternoon Networking & Refreshment Break

3:30 pm

  • CFDA expectations for cell-line development process
  • Analytical requirements for proper characterization & optimization of host cell line
  • Determining performance characteristics of qualified cell lines

QBD, PAT AND EARLY INTERVENTION STRATEGIES

4:00 pm

  • Changes in cell culture conditions affect more than just product yield & glycosylation steps
  • Working to reduce post-translational modifications, which could severely impact drug product quality
  • Happy cells for happy products: metabolite profiling as an indicator of cell line "happiness"

4:30 pm

  • N-Glycans play a critical role in the pharmacology of biotherapeutics
  • N-Glycan analysis has traditionally been a tedious and time-consuming process
  • Next-generation sample preparation and analytical methods shorten time to results from days to hours

5:00 pm

  • Development of a "design space" for integrating CQAs, risk assessment/management and control strategies
  • Identifying process parameters and interactions that adversely affect cell culture performance and product attributes early on, to prevent problems at late-stage cell culture
  • Ensuring consistency in delivery of a cell culture process for therapeutic mAbs

5:30 pm

  • Cell line development as a process
  • How to monitor/control the process
  • Early predictors of final outcomes

6:00 pm

Networking Cocktails

9:00 am

Chairperson's Opening Remarks

Sam Zhang, Senior Principal Scientist/Group Leader, Cell Line Development, Bioprocess R&D, Pfizer Inc, USA

EMERGING CELL CULTURE TECHNOLOGIES AND APPLICATIONS

9:10 am

  • Currently there are no systematic analyses of small molecule function or platform technologies that permit cell culture engineers to rationally harness their potential to control manufacturing performance in a cell line and/or product specific manner
  • Development of a medium to high-throughput platform that enables rapid quantitative assessment of small molecules additives as a tool to create bespoke media environments designed to engineer cell factory function for optimal manufacturing performance

9:40 am

  • Impact of host cell line on product glycosylation
  • Using CRISPR-Cas9 technology to knockout GLUL from HEK293 cells
  • Production of rhEPO using engineered HEK293

10:10 am

Morning Networking and Refreshment Break

10:40 am

  • Importance of structuring appropriate antibody studies that are selective, specific & reproducible
  • Generating genetically humanized mouse models for preclinical antibody efficacy studies
  • Strategies for generating good evaluation data and pitfalls to avoid

THERAPEUTIC MAB INNOVATION AND DISCOVERY

11:10 am

  • Strategies for faster and more efficient selection of suitable clones
  • Ensuring cell-line monoclonality
  • Ensuring cell-line stability and clonal heterogeneity

11:40 am

  • Highlighting the potential to lead to a novel therapy principle for the treatment of diabesity, NASH
  • Dual activation of the GLP-1R and GCGR
  • A novel GLP-1/GCG chimeric peptide/Fc fusion protein - developed and exhibit potent body reduced effect, improvements in multiple metabolic parameters in DIO mouse

12:10 pm

Networking Lunch

NEXT GENERATION CELL LINE ENGINEERING AND EXPRESSION SYSTEMS

1:10 pm

  • Development of alternative expression systems especially for mAb variants without in vivo counterparts, new conjugated formats, or artificial molecules
  • Alternative expression systems offer biopharmaceutical manufacturers the chance to establish a stronger intellectual property position and improve their processes
  • Collaborating to advance novel expression technologies
  • Further advances and demonstration of utility

Moderator:
Sam Zhang, Senior Principal Scientist/Group Leader, Cell Line Development, Bioprocess R&D, Pfizer Inc, USA

 

1:50 pm

  • Novel NGS-integrated approach to identify transcriptionally active site(s) and beyond
  • Constructing landing pad for site specific integration via CRISPR/Cas9-mediated genome editing
  • Design and execute a pooled CRISPR/Cas9 screen using a knowledge-based focused library

2:20 pm

2:40 pm

  • 3D cell culture systems as a new utility tool for cancer stem cell research
  • Revealing a more realistic drug response in 3D culture systems as opposed to conventional culture methods
  • Generating significantly realistic results earlier in epigenetic experiments for more effective translational research

3:10 pm

Afternoon Networking & Refreshment Break

BIOPHARMA DEVELOPMENT & PRODUCTION 2018 CLOSING PLENARY SESSIONS

3:40 pm

  • Enabling drivers of innovation in China
  • Consolidation of local players
  • Shifting investment from manufacturing focus to innovative portfolios
  • Adopting technologies that enable the potential in manufacturing, cell development and biosimilarity
  • Attracting the right talent

4:20 pm

Chairperson's Summary and End of Main Conference Day Two

9:00 am

Analysis is critical in the assurance of quality and compatibility of protein pharmaceuticals, such as biosimilars. However, given the complexity of biotherapeutic products and the analytical processes, analytical artifacts abound. Moreover, many of these artifacts have been overlooked, even the process and results are reproducible. In this workshop, common and crucial artifacts will be reviewed, their mechanisms be discussed and potential solutions be proposed.

What You will learn:
Understanding various artifacts, both false positives and false negatives, exist in the analysis of protein pharmaceuticals.

With specific focus on following areas:

  • A highlight on attributes in relation to chemical transformations, e.g., deamidation and oxidation, during sample preparation.
  • The labile nature of certain protein modifications, such as glycation and trisulfide.
  • Some are attributed to unknown or not pre-defined proteins modifications, such as crosslinking.
  • Artifact of analytical methods

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.


스폰서 모집

이 이벤트의 파트너로 참가하면 인지도를 높일 수 있습니다.
시장을 선도하는 기업으로서의 지위를 확립하고, 브랜딩 및 마케팅을 위한 다양한 기회를 활용할 수 있는 이 이벤트에 많은 관심 부탁드립니다.

파트너

MEDIA PARTNERS

APBN serves as a knowledge exchange platform (print and online) to provide latest news and noteworthy information in biotechnology, healthcare, biomedical and pharmaceutical industry in Asia Pacific. Established in 1997, APBN is the first and only monthly magazine focused on biotechnology, healthcare, pharmaceutical and life science developments in China and other Asia Pacific countries. The main motivation of APBN is to bring biotechnology news in a comprehensive and concise manner to, but not limited to, clinicians, research scientists, students, and other industry professionals and experts.

Bentham Science Publishers is rendering a vital service in the quality publication that publishes over 100 peer-reviewed print and online scientific, technical and medical journals. These titles are indexed in recognized indexing agencies, such as Science Citation Index®, Journal Citation Reports/Science Edition, MEDLINE/Index Medicus, PubMed, Scopus, Chemical Abstracts, EMBASE etc. Some of the high impact titles which enjoy a wide reach and distribution are Current Gene Therapy (Impact Factor 4.906), Current Alzheimer Research (Impact Factor 3.796), Current Medicinal Chemistry (Impact Factor 3.715), and other popular titles.

Bentham has an extensive library of eBooks in the areas of science, technology, medicine, social sciences and humanities. Bentham eBooks publishes monographs, handbooks, conference proceedings, textbooks, review volumes, biographies and autobiographies.

Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.

BioProcess International is a magazine devoted to the development, scale-up, and manufacture of biotherapeutics and biodiagnostics. Each issue provides the global industrial biotherapeutic community with up-to-date, peer-reviewed information detailing the business, politics, ethics, applications, products, and services required to successfully drive biopharmaceuticals, vaccines, and biodiagnostics through the development and manufacturing process.

Established since 1998, Bio-Equip is a leading website for lab equipments, reagents, consumables and bio services. Our users come from different fields like life science, medical research, pharmaceutical, biotechnology, modern agriculture, food safety and environment monitoring. Bio-Equip offer users a complete product directory which involves 158 product ranges among lab equipments, reagents, consumables, lab animals, bio services, cell lines, bio software and books.Serving users through two websites, www.bio-equip.com (Chinese) and www.bio-equip.cn (English), we own over 20,000 registered suppliers and more than 500,000 pieces of product and technical service information with details of product description, price, sample downloading, technical articles and videos.

The Cell Culture Dish and the Downstream Column are online publications designed to provide a community for scientists and others involved in biotechnology. The goal is to share expertise and best practices as well as discuss topics of interest to the community. Articles cover areas important to the application, development and regulatory approval of mammalian cell culture processes and products. This includes biomanufacturing, vaccines, cell culture and purification, regenerative medicine, cord blood stem cells, cellular therapy, cell-based assays, diagnostic antibodies, life science research and related applications.

SOURCE newswire provides comprehensive coverage of breaking news for the life sciences industry in China. Daily updates allow timely tracking of key company developments, deal-making, and regulatory trends, with the primary focus on the pharmaceutical industry.

  • Daily News Briefs: receive 3-4 original articles each day
  • Email alerts on topics of interest by keyword.
  • Access a fully searchable archive of 20,940 original articles
  • Filter news by story type: company news; product/R&D trends; pricing and reimbursement decisions; and general policy developments
  • Ability to save and share favorite news items.

Genetic Engineering & Biotechnology News (GEN) has retained its position as the premier biotech publication since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, including news and analysis as well as webinars, videos, and polls. GEN’s unique news and technology focus covers the entire bioproduct life cycle, including drug discovery, early-stage R&D, applied research (e.g., omics, biomarkers, and diagnostics), bioprocessing, and commercialization.

KONGPOSH Publications is one of the leading Pharma publishers of India. Our publications are – The Pharma Review® is a bi-monthly article based journal. Covering news, views and articles on various fields of pharmacy including Clinical Trials, Biotechnology, Review/Research papers, Herbal Medicine and much more. Contributions received from Eminent pharma personalities from India as well as other countries which helps us to have a varied and rich content matter. Participation and distribution in over 20 Expos & Conferences worldwide each year. It is widely read by decision makers, middle management and the academia. The journal is Abstracted & Indexed in International Pharmaceutical Abstract & Chemical Abstract - USA, Index Copernicus - Poland & Ulrich’s Journal Database– USA for the quality of its content. Also available on our website and E-book format.

For regular complimentary link of the journal write to us on kongposhpub@gmail.com.

Lingmed Ltd was founded in 2013 in Hong Kong, currently we have offices in Shanghai and Beijing. Lingmed promotes three leading intelligence databases for healthcare professionals in China to make better decisions. Lingmed’s core products are healthcare intelligence databases; it covers global innovative assets & China market intelligence. Lingmed’s Products and Services have been recognized by Fortune 500 multinational pharma and device companies as well as Chinese local big pharmacos. In addition, we together with our partners in Europe provide partnering services to bridge European and Chinese pharmaceuticals with biotech companies, including valuation and market monitoring reports.

In the realm of Pharmacy, where innovation is rapid, Pharmaceutical-Tech stands adept at conceptualizing unique ideas relevant to the B2B space. Pharmaceutical-Tech is essentially a B2B online business, technology media platform and global magazine that have under its wraps the largest global database of Pharmacy buyers and suppliers. Pharmaceutical-Tech.com covers in-depth trends that shape industry dynamics and metamorphose global economics. With services like search engine optimization, global magazine, social media marketing, product video showcase, e-mail marketing, e-newsletter sponsorship, banner advertising, event marketing and micro-website within our platform, www.pharmaceutical-tech.com has created a recognition that spans over a global audience, thereby revolutionizing how businesses transact.

Pharma China (www.pharmachinaonline.com) is the most trusted English media and business intelligence service covering the Chinese pharmaceutical / biopharmaceutical industry and market.

Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China's burgeoning but increasingly complex healthcare marketplace, and is subscribed by most multinational pharmaceutical companies, leading CROs, investment banks and consulting firms active in China as well as relevant industry associations and government agencies.

  • Pharma China Journal Edition (monthly in PDF and Print)
  • Pharma China Web Edition (continuously-updated news, in-depth commentaries and online databases)
  • China Pharmaceutical Guide (the most comprehensive and authoritative reference for China's healthcare sector)

Pharma Focus Asia is a quarterly magazine from Ochre Media Pvt. Ltd. Pharma Focus Asia covers important issues and trends shaping the future of the Pharma industry across Asia and rest of the world. It is the leading Pharma title in print as well as digital versions serving the information needs of key executives from the world's leading pharmaceutical companies.

Informa's Pharma Intelligence is the trusted partner of the top 50 global pharmaceutical companies and the top 10 contract research organisations (CRO's) – providing timely intelligence and insight to help them make authoritative decisions.

From drug and device discovery and development to regulatory approval, drug reimbursement to lifecycle management – we provide the global intelligence and insight to help advance our partners' initiatives in a fast changing market.

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide.

Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.

Technology Networks scientific communities offer today's scientists a single resource that contains unique, engaging, and entertaining content from their field of research.

연사

Xu Wei

Vice President, Manufacturing, Innovent Biologics, China

Abrar Mir

Managing Partner, Quadria Capital Investment Management Pte Ltd, Singapore

Wang Honglou

CIO, livzon Pharmaceutical Group, China

Jerry Clifford

Chief Operating Officer, Valitacell, Ireland

George Hutchinson

Head of Global Distribution, Solentim

Dr Zhang Peiqing

Analytical Science and Technology Coordinator, Novartis

Sunny Zhou

Professor, Department of Chemistry and Chemical Biology Faculty Fellow, Barnett Institute of Chemical and Biological Analysis Northeastern University, Boston, Massachusetts

Dr. John Yan

Applications Scientist, ProZyme

Hung Fai Poon

Chief Scientific Officer, Zhejiang Hisun Pharmaceutical Co., Ltd, China

Prof. David James

University of Sheffield

Ng Say Kong

Staff Scientist, Animal Cell Technology 2, Bioprocessing Technology Institute, A*STAR

Qingcong Lin

Vice-President, Shenogen Pharma Group, China

Shaoqing Yang

Vice President, Zhejiang Doer Biologics Co.

Jian Dong

VP & Site Head of Manufacturing, Wuxi AppTec, China

Dr. Jinyou Zhang

Senior Vice President/Head, Bio Development and Manufacturing, BeiGene Co. Ltd., China

David Sadler

President & CEO, Kunshan Zotek Kinglai Co. Ltd. U.K.

Wendy Chiang

Managing Director of Microbial Solutions, Greater China Region, Charles River Laboratories

Dr Yvan Ruland

Technology Manager Biopharma, Novasep, China

Bo Qi

M.Sc. Vice President Head of CMC General Manager, Generon Beijing, China

Joycelyn Kwek

Former Director, Quality Assurance, Amgen Singapore

Hui Cai

Head of QC Laboratory 2 & Head of Microbial Control Team, WuXi Biologics, China

Dr. Dennis Yu Xia

Vice President of Manufacturing and Quality, Akeso Bio, China

Dr. John Zeng

Executive Vice President, Bioprocess Development & Pilot Plant Manufacturing, Shanghai Zerun Biotech Co Ltd, China

Grace Zheng

Head of Bioprocess, ZaiLab, Ltd.

Noel Rob

Business Development Manager, Pall Life Sciences, UK

Dr. Christopher J. Hickey

Senior Director Government Affairs, Market Access & Communications, Pfizer

Dr. Scott Liu

President and CEO, Shanghai Henlius Biotech Inc.

Dr. Lutz Hilbrich

Head Strategic Task Force Biologics, Sanofi

Jiang Junjun

Assistant Director, WuXi Biologics

Wen Yong

Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu Aosaikang Pharmaceutical Co Ltd, China

Dr. Jacqueline Ming Liu

Vice President, TOT Biopharma, China

Dr Qiwei Wu

Ph.D, Vice President of Process Development and Manufacturing, Livzon Mabpharma

Dr Amy Hong Que

Vice President - Quality, Innovent Biologics

Ai-Min Hui

Chief Medical Officer, Shanghai Fosun Pharma

Prof. Dr. Florian Turk

Head Global Payor Marketing, Sales and Relations, Sandoz Biopharmaceuticals Sandoz International GmbH, Germany

Pearl Fong

Associate Vice President, Division of Project Development, Mycenax Biotech Inc., Taiwan

Bryan Kim

Vice President of Business Development, Samsung Bioepis, Korea

Dr. Xin Zhang

Head of Global Clinical Operations and Affairs, Shanghai Henlius Biotech Co Ltd, China

Sunit Maity

Director, Product Development, Zumutor Biologics, India

MinSeob Lee

Team Leader of R&D CMC/PM, Celltrion R&D, Korea

Mitul Agarwal

General Manager - Business Development & Licensing, Intas Pharmaceuticals, India

Alvin Luk

Senior Vice President and Chief Medical Officer - Global Clinical Operations and Affairs, Shanghai Henlius Biotech Co Ltd, China

Dr Jun Yuan

Vice President, Quacell Biotech, China

Jerry Yang

SVP, Process & Product Development, Hangzhou JUST Biotherapeutics Co., Ltd., China

Dong Huifang

Director of Cell Line Development, WuXi Biologics, China

Eric Chang

Head of Cell Line Development, JHL Biotech, Taiwan

Sam Zhang

Senior Principal Scientist/Group Leader, Cell Line Development, Bioprocess R&D, Pfizer Inc, USA

Debby Chang

Associate Director - Cell Line Engineering and Development, Shanghai Hengrui Pharmaceutical, China

Sai Ling Liu

Chief Scientific Officer, Surfer Biotech, China

Wen Zaiqing

Vice President of CMC, Generon Corpoation (Shanghai) Limited, China

Dr. Li Shi

Chief Executive Officer, Shanghai Zerun Biotech Co. Ltd

Eric Liu

China Biosimilars Regulation Publishing Manager, Pfizer

Zheru Zhang

President, I-Mab Biopharma, China

Zack Zheng

Ph.D. VP of Process Development (Wuhan), JHL BioTech, China

Masayoshi Nagaya

Sr. Global Technology Manager, JSR Life Sciences

Dr. Frank Ye

SVP of Manufacturing and Quality, Hangzhou Just Biotherapeutics Co., Ltd., China

John Dubczak

Director of Operations, Charles River Laboratories, U.S.

Dr. Bin Wang

Head of Business Development, Boehringer Ingelheim Biopharmaceuticals, China

Yifang Wu

President, Wanbang Biopharmaceuticals Co., Ltd, China

Iris Desiree Sioson

Reliability Manager, APAC, Envirotainer, Singapore

Lim Swee Nguan

Director of Asia Pacific Sales, Finesse, part of Thermo Fisher Scientific, Singapore

개최 기간 및 개최지

2018년 5월 15-17일

Hilton Shanghai Hongqiao
No. 1116 Hong Song East Rd, Shanghai, 201103, China
Tel: +86-21-3323 6666

메일링 서비스
메일링 서비스